Study wrapper · #628
Anticoagulant Effects of Arginine-Containing Peptides of the Glyproline Family (His-Phe-Arg-Trp-Pro-Gly-Pro and Thr-Lys-Pro-Arg-Pro-Gly-Pro) Revealed by Thromboelastography.
Editor's note
This is a small in-vitro coagulation study, not a clinical one. Using thromboelastography, researchers tested three glyproline peptides — including Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — across concentrations and reported that all shifted clotting parameters (R, K, MA, S, TMA, J) toward hypocoagulation versus control, with Selank showing the greatest anticoagulant potency of the three. For Selank, best known for anxiolytic and immunotropic effects, an anticoagulant signal is a peripheral but noteworthy property. Weigh it cautiously: thromboelastography is a benchtop assay on blood samples, not an in-vivo bleeding or thrombosis outcome, and no doses, sample sizes, or safety endpoints are described in the abstract. These are preclinical findings; human data are needed before clinical conclusions can be drawn, and the result is most useful as a flag that Selank may interact with coagulation.
Plain-language abstract
Selank is a peptide studied mainly for anxiety, but researchers also wanted to know whether it affects blood clotting. They used thromboelastography, a laboratory technique that measures how blood forms a clot over time, and tested three related short peptides — including Selank — at various concentrations. All three peptides pushed the clotting measurements in the direction of slower, weaker clotting compared with untreated samples. Of the three, Selank had the strongest anti-clotting effect. This was a test-tube study on blood samples, not a study in animals or people, and it did not report doses, how many samples were tested, or any bleeding-related outcomes. It suggests Selank may influence the clotting system, which is worth noting but needs confirmation in living subjects before any practical meaning can be drawn.